PERTH, Australia – Unlike its Australian peers, regenerative medicine company Regeneus Ltd. is not focusing on the U.S. market. Instead, it's placing its bets on Japan first and then will move out to other territories.
PERTH, Australia – A Senate inquiry on research funding models for cancers with low survival rates has returned a report that outlines 25 recommendations to improve infrastructure, clinical trials and reimbursement processes for cancer drugs in Australia.
PERTH, Australia – After years of consultations and pressure from industry, Australia's Therapeutic Goods Administration (TGA) will finally begin regulating autologous cell and tissue products as biologicals.
PERTH, Australia – Unlike its Australian peers, regenerative medicine company Regeneus Ltd. is not focusing on the U.S. market. Instead, it's placing its bets on Japan first and then will move out to other territories.
PERTH, Australia – After years of consultations and pressure from industry, Australia's Therapeutic Goods Administration (TGA) will finally begin regulating autologous cell and tissue products as biologicals.
DUBLIN and PERTH, Australia – Sensorion SA is teaming up with Cochlear Ltd. to explore the potential for combining drug therapy with cochlear implant surgery to improve patient outcomes.
DUBLIN and PERTH, Australia – Sensorion SA is teaming up with Cochlear Ltd. to explore the potential for combining drug therapy with cochlear implant surgery to improve patient outcomes. The two companies will spend next year evaluating Sensorion's clinical-stage drug candidate, SENS-401, with Cochlear's implantable devices in a number of preclinical models. If that work is successful, clinical trials could follow in 2019.
